Financial reports
10-Q
2023 Q1
Quarterly report
12 Jan 24
10-K
2023 FY
Annual report
20 Nov 23
10-Q
2023 Q3
Quarterly report
14 Jul 23
10-Q
2023 Q2
Quarterly report
14 Apr 23
10-Q
2023 Q1
Quarterly report
17 Jan 23
10-K
2022 FY
Annual report
25 Nov 22
10-Q
2022 Q3
Quarterly report
14 Jul 22
10-Q
2022 Q2
Quarterly report
11 Apr 22
Current reports
8-K
Entry into a Material Definitive Agreement
21 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
8-K
Other Events
1 Mar 24
8-K
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
16 Feb 24
8-K
Other Events
30 Jan 24
8-K
Regulation FD Disclosure
24 Jan 24
8-K
Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide
4 Jan 24
8-K
Other Events
3 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Oct 23
8-K
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
16 Oct 23
Registration and prospectus
424B3
Prospectus supplement
20 Mar 24
S-1
IPO registration
12 Mar 24
D
$3.60 mm in options, sold $3.60 mm, 2 investors
16 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
POS AM
Prospectus update (post-effective amendment)
24 Jan 24
S-8
Registration of securities for employees
18 Jan 24
424B3
Prospectus supplement
8 Dec 23
S-1
IPO registration
30 Nov 23
D
$1.57 mm in options, sold $1.57 mm, 1 investor
4 Oct 23
424B5
Prospectus supplement for primary offering
2 Oct 23
Proxies
DEF 14A
Definitive proxy
6 Mar 24
DEF 14A
Definitive proxy
23 Aug 23
PRE 14A
Preliminary proxy
9 Aug 23
DEF 14A
Definitive proxy
22 Mar 23
PRE 14A
Preliminary proxy
10 Mar 23
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
DEF 14A
Definitive proxy
14 May 21
DEF 14A
Definitive proxy
26 May 20
Other
EFFECT
Notice of effectiveness
21 Mar 24
EFFECT
Notice of effectiveness
29 Jan 24
EFFECT
Notice of effectiveness
11 Dec 23
CORRESP
Correspondence with SEC
6 Dec 23
UPLOAD
Letter from SEC
6 Dec 23
EFFECT
Notice of effectiveness
9 May 23
CORRESP
Correspondence with SEC
5 May 23
CORRESP
Correspondence with SEC
5 May 23
CORRESP
Correspondence with SEC
4 May 23
CORRESP
Correspondence with SEC
4 May 23
Ownership
3
Nelson Cabatuan
15 Mar 24
SC 13D/A
Boos Wayne W
14 Feb 24
SC 13G/A
Invenomic Capital Management LP
14 Feb 24
4
Vanessa Carle
1 Nov 23
4
JOHN MARTIN DOCHERTY
30 Oct 23
4
CHRISTOPHER BUNKA
30 Oct 23
SC 13D
Boos Wayne W
18 Sep 23
4
Nicholas W Baxter
25 Jul 23
4
William Edward McKechnie
25 Jul 23
4
ALBERT L REESE JR
25 Jul 23